

DAFTAR PUSTAKA

1. Prasetyo PD, Pawitra I, Wijaya I. Expression of TTF-1 and CK-7 in the diagnosis of pleural effusion cytology suspected lung adenocarcinoma. *J Biomed Transl Res*. 2015; 1(1):22-26.
2. Roy-Chowdhuri S, Aisner DL, Allen TC, et al. Biomarker testing in lung carcinoma cytology specimens: a perspective from members of the Pulmonary Pathology Society. *Arch Pathol Lab Med*. April 2016:arpa.2016-0091-SA-7.
3. da Cunha Santos G, Saieg MA. Preanalytic parameters in epidermal growth factor receptor mutation testing for non-small cell lung carcinoma: a review of cytologic series. *Cancer Cytopathol*. 2015; 123(11): 633–643.
4. Seki Y, Fujiwara Y, Kohno T, et al. Circulating cell-free plasma tumor DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression. *ESMO Open*. 2018; 3(2):e000292. <https://doi.org/10.1136/esmoopen-2017-000292>
5. Jusuf A, Putra AC. Pandangan umum pengobatan kanker paru. In: Jusuf A, editor. *Pengobatan kanker paru*. Jakarta: Penerbit Universitas Indonesia; 2019.p.1-7.
6. Kobayashi K, Kagamu H. EGFR mutant. In: Takiguchi Y, editor. *Molecular targeted therapy of lung cancer*. 1st ed. Singapore: Springer Science Business Media; 2017.p.167-89.
7. Syahrudin E, Wulandari L, Muktiati NS, Rima A, Ermayanti S, Levi M, et al. Uncommon EGFR mutations in cytological specimens of 1.874 newly diagnosed Indonesian lung cancer patients. *Dove Press j: Lung cancer: Targets and therapy*. 2018; 9: 25-34.
8. Reck M, Hagiwara K, Han B, Tjulandin S, Grohe C, Yokoi T, et al. Circulating Free Tumor-derived DNA (ctDNA) Determination of *EGFR* Mutation Status in European and Japanese Patients with Advanced NSCLC: the ASSESS Study. *J Thorac Oncol*. 2016; 11(10):1682-9.
9. Bernicker EH. Liquid biopsies. In: Cagle PT, Beasley MB, Dacic S, Kerr KM, Portier B, Allen TC, Chirieac LR, Borczuk AC, Sholl LM, Bernicker EH, editors. *Precision molecular pathology of lung cancer*. 2nd ed. Switzerland: Springer International Published; 2018.p.275-86.
10. Zaini J, Syahrudin E, Muhammad Y, Andarini SL, Hudoyo A, Masykura N, et al. Evaluation of PCR-HRM, RFLP, and direct sequencing as simple and cost-effective methods to detect common *EGFR* mutations in plasma

- cell-free DNA of non-small cell lung cancer patients. Wiley Cancer Reports. 2019; 22(3): <http://doi.org/10.1002/cnr2.1159>.
11. Pecorino L. Molecular biology of cancer - mechanisms, targets, and therapeutics. 3rd ed. Oxford (UK): Oxford University Press: 2012.
 12. Jusuf A, Wibawanto A, Icksan AG, Syahrudin E, Juniarti, dkk. Kanker paru jenis karsinoma bukan sel kecil. Pedoman diagnosis dan penatalaksanaan di Indonesia. PDPI, Jakarta. 2018; 1-42.
 13. Jack ID, Shaw AT. Tumor heterogeneity and resistance to cancer therapies. Nature Reviews, Clinical Oncology. 2017; 1-14.
 14. Alaoui HL, Hassan O, Yang YW, Buchanan P. Lung cancer: biology and treatment options. Biochim Biophys Acta. 2015; 1856(2): 189-210.
 15. Larsen JE, Fong KM. Non-small cell lung neoplasms: Biological basis of non-small cell lung neoplasms. In: Cameron RB, Gage DL, Olevsky O, editors. Modern thoracic oncology. New Jersey: World Scientific. 2018; 2: 33-59.
 16. Paramothayan S. Lung Cancer. In: Paramothayan S, editor. Essential respiratory medicine, 1st ed. West Sussex, UK: John Wiley and Sons Ltd; 2019.p.205-33.
 17. Paoulsen TT, Poulsen HS, Pappot H. Molecular biology of lung cancer. In: Hansen H, editor. Textbook of Lung Cancer. 2nd ed. London: Informa Healthcare; 2008.p.20-34.
 18. Bray F, Ferlay J, Seorjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018; 68: 394-424.
 19. de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Transl Lung Cancer Res. 2018; 7(3): 220-33.
 20. Wistuba II, Brambilla E, Noguchi M. Classic anatomic pathology and lung cancer. In: Pass HI, Ball D, Scagliotti GV, editors. IASLC Thoracic Oncology. 2nd ed. Philadelphia: Elsevier Inc; 2018.p.143-63.
 21. DeRouen MC, Hu L, McKinley M, Gali K, Patel M, Clarke C, et al. Incidence of lung cancer histologic cell-types according to neighborhood factors: A population based study in California. Plos one. 2018; 13(5): 1-15. <https://doi.org/10.1371/journal.pone.0197146>
 22. Yatabe Y, Kerr KM, Utomo A, Rajadurai P, Tran VK, Du X, et al. *EGFR* Mutation Testing Practices within the Asia Pacific Region - Results of a Multicenter Diagnostic Survey. J Thorac Oncol. 2015; 10: 438-45.

23. Indonesia – Global Cancer Observatory. Internasional Agency for Research on Cancer – World Health Organization. 2018. <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-factsheets.pdf>. Accessed July 27, 2019.
24. Aini SR, Wulandari L, Andajani S. Lung cancer patients' profile in Dr. Soetomo General Hospital Surabaya 2016-2017. *Journal of Aesculap Medical Science*. 2019; 10(1): 44-7.
25. Hulma MA, Basyar M, Mulyani H. Hubungan karakteristik penderita dengan gambaran sitopatologi pada kasus karsinoma paru yang dirawat di RSUP Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas*. 2014; 3(2): 196-201.
26. Cheng TD, Cramb SM, Baade PD, Youlten DR, Nwogu C, Reid ME. The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. *J Thorac Oncol*. 2016; 11(10): 1653-71.
27. Haugen A, Mollerup S. Etiology of lung cancer. In: Hansen H, editor. *The Textbook of Lung Cancer*. 2nd ed. Denmark: National University Hospital Copenhagen Denmark. 2008; 1: 1-9.
28. I Dewa Gede Sukardja. *Biologi tumor: Onkologi Klinik*. Ed 2. Airlangga university press. 2000: 13-83.
29. Malumbres M. Protein family review - Cyclin-dependent kinases. *Biomed Central*. 2014; 15(6):122-32.
30. Baba AL, Catoi C. Carcinogenesis. In: Baba AL, editor. *Comparative oncology*. 1st ed. Bucharest: The Publishing House of the Romanian Academy. 2007; 2: 98-120.
31. Croce CM. Molecular origins of cancer - Oncogenes and cancer. *N Engl J Med*. 2008; 358: 502-11.
32. Benepal T, Matakidou A, Zee Y, Houlston R, Eisen T. Genetics of lung cancer: in *The textbook tumors of the chest*. 2006: 57-66.
33. Arends MJ. Carcinogenesis and neoplasia. In: Cross SS, editor. *Underwoods pathology: a clinical approach USA*: Elsevier Inc.; 2013.p.183-219.
34. Siddiqui IA, Sanna V, Ahmad N, Sechi M, Mukhtar H. Resveratrol nanoformulation for cancer prevention and therapy. *Ann. N. Y Acad. Sci*. 2015; 134: 20-31.

35. Devi PU. Basic of carsinogenesis. Health Administrator. 2005; 17(1): 16-24.
36. Zaini J, Andriani R, Susanto AD, Rosrita NN, Jusuf A. Rokok dan kanker paru. In: Jusuf A, editors. Dasar-dasar diagnosis kanker paru. Jakarta: Penerbit Universitas Indonesia; 2017.p.25-46.
37. Putra AC, Nurwidya F, Zaini J, Andarini S. Aspek biomolekuler kanker paru. In: Jusuf A, editor. Dasar-dasar diagnosis kanker paru. Jakarta: Penerbit Universitas Indonesia; 2017.p.103-11.
38. Hanahan D, Weinberg RA. Hallmarks of cancer: an organizing principle for cancer medicine. In: Devita VT, Lawrence TS, Rosenberg SA, editors. Cancer - principle and practice of oncology. 10th ed. Philadelphia: Wolter Kluwer Health; 2015.p.24-44.
39. Morgensztern D, Devarakonda S, Mitsudomi T, Maher C, Govindan R. Mutational event in lung cancer: Present and developing technologies. In: Pass HI, Ball D, Scagliotti GV, editors. IASLC Thoracic Oncology. 2nd ed. Philadelphia: Elsevier Inc; 2018.p.95-103.
40. Wagener C, Stocking C, Muller O. Cancer Signaling. 1st ed. Weinheim: Wiley-VCH; 2017.p.97-118.
41. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor mutations in lung cancer. Nature Publishing Group. 2007; 7: 169-81.
42. Collin AA, Hubert P, Crémel G, Bennisroune A. Role of ErbB reseptor in cancer cell migration and invasion. Front. Pharmacol. 2015; 6: 283-93.
43. Kim L, Liu G, Tsao MS. Predictive tumor biomarkers for EGFR inhibitors. In: Roth JA, Hong WK, Komaki RU, Tsao AS, Chang JY, Blackmon SH, editors. Lung Cancer - Wiley Blackwell. 4th ed. Hoboken, New Jersey: John Wiley & Sons, Inc; 2014.p.435-53.
44. Canales JR, Cuentas EP, Wistuba I. Diagnosis and molecular classification of lung cancer. In: Reckamp KL, editor. Lung cancer, treatment and research. Switzerland: Springer International Published; 2016.p.25-46.
45. Herbst RS, Heymach JV, Lippman SM. Molecular origins of cancer: Lung Cancer. N Engl J Med. 2008; 359: 1367-80.
46. Ciardiello F, Tortora G. EGFR antagonist in cancer treatment. N Engl J Med. 2008; 358: 1160-74.
47. Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014; 32:1-8.

48. Stanta G, Borin S. Overview on clinical relevance of intra-tumor heterogeneity. *Fron. Med.* 2018; 5(85). <https://www.frontiersin.org/articles/10.3389/fmed.2018.00085/full>
49. Palmirotta R, Lovero D, Cafforio P, et al. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. *Ther adv Med Oncol.* 2018; 10:1-24.
50. Haber DA, Velculescu VE. Blood-base analyses of cancer: circulating tumor cell and circulating tumor DNA. *Cancer Discov.* 2014; 4(6) 650-61.
51. Rolfo C, Mack PC, Scagliotti GV, et al. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC. *J Thorac Oncol.* 2018; 13(9): 1248-68.
52. Lianidou E, Pantel K. Liquid biopsies. *Genes Chromosomes Cancer.* 2019; 58: 219-23.
53. Polivka J, Pesta M, Janku F. Testing for oncogenic molecular aberration in cell-free DNA-base liquid biopsies in the clinic: are we there yet?. *Expert Rev. Mol. Diagn.* 2015;1-14.
54. Sopriyudi D. Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan. Jakarta: Salemba Medika; 2010.p.81-5.
55. Centers for Disease Control and Prevention (CDC). National Health Interview Survey (NHIS), Adult tobacco Use. USA; 2017. <https://www.cdc.gov/hchs/nhis/tobacco>.
56. Ryan H, Trosclair A, Gfroerer J. Adult current smoking: differences in definitions and prevalence estimates – NHIS and NSDUH, 2008. *Journal of Environmental and Public Health.* 2012; 11: [doi:10.1155/2012/918368](https://doi.org/10.1155/2012/918368).
57. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin.* 2018;68:7-30.
58. Haugen A, Mollerup S. Etiology of lung cancer. In: Hansen H, editor. *Textbook of Lung Cancer.* 2nd ed. London: Informa Healthcare; 2008.p.1-9.
59. Cancer Research UK. Lung Cancer Statistik 2015-2017. London: Cancer Research UK; 2019. <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer>.
60. American Cancer Society. Cancer Facts & Figures 2018. Atlanta: American Cancer Society; 2018. <https://www.cancer.org/cancer/cancer-facts-figures>

61. Couraud S, Souquet PJ, Paris C, Do P, Doubre H, Pichon E, et al. BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers. *Eur Respir J*. 2015; 45: 1403-14.
62. Prokhorov AV, Hudmon KS. Smoking prevention and cessation. In: Roth JA, Hong WK, Komaki RU, Tsao AS, Chang JY, Blackmon SH, editors. *Lung Cancer* - Wiley Blackwell. 4th ed. Hoboken, New Jersey: John Wiley & Sons, Inc; 2014.p.435-53.
63. Taufik FF, Susanto AD, Simarmata E, Faisal HD, Jusuf A. Faktor risiko kanker paru. In: Jusuf A, editors. *Dasar-dasar diagnosis kanker paru*. Jakarta: Penerbit Universitas Indonesia; 2017.p.11-23.
64. Arends MJ. Carcinogenesis and neoplasia. In: Cross SS, editor. *Underwood's pathology: a clinical approach*. 1st ed. USA: Elsevier Inc; 2013.p.183-219.
65. Wang P, Zou J, Wu J, Zhang C, Ma C, Yu J, et al. Clinical profiles and trend analysis of new diagnosed lung cancer in a tertiary care hospital of East China during 2011-2015. *J Thorac Dis*. 2017; 9(7): 1973-9.
66. Okamoto I, Morita S, Tashiro N, Imamura F, Inoue A, Seto T, et al. Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: long-term follow-up of a large patient cohort. *Elsevier B.V*. 2018; 117: 14-9.
67. Knight SB, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C. Progress and prospects of early detection in lung cancer. *Open Bio*. 2017; 7 <http://dx.doi.org/10.1098/rsob.170070>
68. Hardavella G, Sethi T. Epidemiology: development and perspectives. In: Dingemans AMC, Reck M, Westeel V, editors. *ERS Monographs - Lung cancer*. 1st ed. Sheffield: European Respiratory Society; 2015.p.1-11.
69. Ellis PM, Vandermeer R. Delays in diagnosis of lung cancer. *J Thorac Dis*. 2011; 3: 183-8.
70. Sari CYI, Yunus F, Syahrudin E. Proporsi pasien kanker paru dengan riwayat keterlambatan diagnosis akibat didiagnosis sebagai tuberkulosis paru. *J Respir Indo*. 2019; 39(2): 92-102.
71. Soetandyo N, Hanafi AR, Agustini S, Sinulingga DT. Prognosis of advanced stage non-smallcell lung cancer patients receiving chemotherapy: adenocarcinoma versus squamous cell carcinoma. *Med J Indones*. 2020; 29: 26-31.

72. Kementrian Kesehatan Republik Indonesia Komite Penanggulangan Kanker Nasional. Pedoman Nasional Pelayanan Kedokteran - Kanker Paru. 1st ed. Jakarta: Kemenkes; 2017.p.1-75.
73. Soehardiman D, Jusuf A, Andriani R, Gozali A, Suhendra U, Suhendra U, et al. Diagnosis dan staging invasif untuk kanker paru. In: Jusuf A, editors. Dasar-dasar diagnosis kanker paru. Jakarta: Penerbit Universitas Indonesia; 2017.p.169-87.
74. Roy-Chowdhuri S, Aisner DL, Allen TC, et al. Biomarker testing in lung carcinoma cytology specimens: a perspective from members of the Pulmonary Pathology Society. *Arch Pathol Lab Med*. 2016; 140: 1267-72.
75. da Cunha Santos G, Saieg MA. Preanalytic parameters in epidermal growth factor receptor mutation testing for non-small cell lung carcinoma: a review of cytologic series. *Cancer Cytopathol*. 2015; 123(11): 633-43.
76. Denis MG, Lafourcade MP, Garff GL, Dayen C, Falchero L, Thomas P, et al. Circulating free tumor-derived DNA to detect EGFR mutations in patients with advanced NSCLC: French subset analysis of the ASSESS study. *J Thorac Dis*. 2019; 11(4): 1370-8.
77. Mok TS, Peters S, Tan DSW, Ares LP, Park K. Therapeutic perspectives. In: Mok TS, Carbone DP, Hirsch FR, editors. IASLC atlas of EGFR testing in lung cancer. Colorado: International Association for the Study of Lung Cancer (IASLC); 2017.p.13-17.
78. Chen LY, Molina-Vila MA, Ruan SY, Su KY, Liao WI, Yu KL, et al. Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: a systematic review and meta-analysis. *Lung cancer*. 2016; 94: 46-53.
79. Woodard GA, Jones KD, Jablons DM. Lung cancer staging and prognosis. In: Reckamp KL, editor. Lung cancer – treatment and research. Switzerland: Springer International Publishing; 2016.p.47-75.
80. Ha SY, Choi SJ, Cho JH, Choi HJ, Lee J, Jung K, et al. Lung cancer in never-smoker Asian female is driven by oncogenic mutations, most often involving EGFR. *Oncotarget*. 2015; 6(7): 5465-74.
81. Li X, Ren R, Ren S, Chen X, Cai W, Zhou F, et al. Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients. *Translational Oncology*. 2014; 7(3): 341-8.
82. Tseng CH, Chiang CJ, Tseng JS, Yang TY, Hsu KH, Chen KC, et al. EGFR mutation, smoking, and gender in the advanced lung adenocarcinoma. *Oncotarget*. 2017; 8(58): 98384-93.

83. Ren JH, He WS, Yan GL, Jin M, Yang KY, Wu G. EGFR mutation in non-small-cell lung cancer among smokers and non-smokers: a meta-analysis. *Environ Mol Mutagen*. 2012; 53: 78-82.
84. Pham DK, Kris MG, Riely GJ, Sarkaria IS, McDonough T, Chuai S, et al. Use of cigaret-smoking history to estimate the likelihood of mutations in egidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. *J Clin Oncol*. 2006; 24: 1700-4.
85. Wiencke JK, Thurston SW, Kelsey KT, Varkonyi A, Wain JC, Mark EJ. Early age at smoking initiation and tobacco carsinogen DNA damage in the lung. *J Natl Cancer Inst*. 1999; 91: 614-9.
86. Oh AC, Lee JK, Kim JY, Jin HO, Jung JW, Chang YH, et al. Utilization of archived plasma to detect epidermal growth factor receptor mutation in non-small cell lung cancer patients. *Biopreservation and Biobanking*. 2019; 17(4): 319-25.
87. Zhang S, Zhu L, Cheng X, Zhang X, Chen E, Fang H, et al. ctDNA assessment of EGFR mutation status in Chinese patients with advanced non-small cell lung cancer in real world setting. *J Thorac Dis*. 2018; 10(7): 4169-77.
88. Thress KS, Brant R, Carr TH, Dearden S, Jerkins S, Brown H, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. *Elsevier*. 2015; 90: 509-15.
89. Arriola E, Lario AP, Gomez RG, Tain PD, Constenla M, Marquez G, et al. comparison plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS. *Clinical and Translational Oncology*. 2018; 20: 1261-7.
90. Xu H, Baidoo AAH, Su S, Ye J, Chen C, Xie Y, et al. A comparison of EGFR muation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients. *Transl Lung Cancer Res*. 2019; 8(2): 135-43.
91. Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, et al. *Clin Cancer Res*. 2006; 12(13): 3915-21.
92. Pusponegoro HD, Wirya IGNW, Pudjiadi AH, Bisanto J, Zukarnain SZ. Uji diagnostik. In: Sastroasmonro S, Ismael S, editors. *Dasar-dasar metodologi penelitian klinis*. Jakarta: Agung Seto; 2014.p.219-44.
93. Gu J, Zang W, Liu B, Li L, Huang L, Li S, et al. Evaluation of digital PCR for detecting low-level EGFR mutations in advanced lung adenocarcinoma

patients: a cross-platform comparison study. *Oncotarget*. 2017; 35(3): 157-68.

94. Qiu M, Wang J, Xu Y, Ding X, Li M, Jiang F, et al. Circulation tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis. *Cancer Epidemiol Biomarkers Prev*. 2015; 24(1): 206-12.
95. Khoo C, Rogers TM, Fellowes A, Bell A, Fox S. Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. *Transl Lung Cancer Res*. 2015; 4: 126-41.
96. Normanno N, Denis MG, Thress KS, Ratcliffe M, Reck M. Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small cell lung cancer. *Oncotarget*. 2017; 8(7): 12501-16.
97. Yung TKF, Chan KCA, Mok TSK, Tong J, To KF, Lo YMD. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. *Clin Cancer Res*. 2009; 15(6): 2076-84.
98. Wan JCM, Massie C, Corbacho JG, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. *Macmillan Publisher Limited*. 2017; 7: [doi: 10.1038/nrc.2017.7](https://doi.org/10.1038/nrc.2017.7)

